Longfa Xu

768 total citations
28 papers, 386 citations indexed

About

Longfa Xu is a scholar working on Cardiology and Cardiovascular Medicine, Infectious Diseases and Epidemiology. According to data from OpenAlex, Longfa Xu has authored 28 papers receiving a total of 386 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Cardiology and Cardiovascular Medicine, 13 papers in Infectious Diseases and 13 papers in Epidemiology. Recurrent topics in Longfa Xu's work include Viral Infections and Immunology Research (23 papers), Viral gastroenteritis research and epidemiology (12 papers) and Herpesvirus Infections and Treatments (7 papers). Longfa Xu is often cited by papers focused on Viral Infections and Immunology Research (23 papers), Viral gastroenteritis research and epidemiology (12 papers) and Herpesvirus Infections and Treatments (7 papers). Longfa Xu collaborates with scholars based in China and United States. Longfa Xu's co-authors include Tong Cheng, Ningshao Xia, Lisheng Yang, Hai Yu, Xiangzhong Ye, Qinjian Zhao, Yuqiong Que, Shuxuan Li, Zhiqun Li and Rui Zhu and has published in prestigious journals such as PLoS ONE, Journal of Virology and Scientific Reports.

In The Last Decade

Longfa Xu

26 papers receiving 381 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Longfa Xu China 13 291 206 141 112 101 28 386
Damian Guang Wei Foo Singapore 7 455 1.6× 374 1.8× 222 1.6× 77 0.7× 138 1.4× 9 546
Qunying Mao China 12 476 1.6× 274 1.3× 216 1.5× 128 1.1× 146 1.4× 28 526
Yanchun Che China 13 237 0.8× 203 1.0× 72 0.5× 150 1.3× 133 1.3× 37 446
Thomas Wilton United Kingdom 8 180 0.6× 320 1.6× 38 0.3× 79 0.7× 82 0.8× 14 412
Chenghong Dong China 13 374 1.3× 306 1.5× 152 1.1× 122 1.1× 142 1.4× 29 536
Ken Honzumi Japan 9 223 0.8× 189 0.9× 98 0.7× 177 1.6× 67 0.7× 12 399
Juhana Santti Finland 8 509 1.7× 367 1.8× 85 0.6× 238 2.1× 120 1.2× 8 581
D.C. Pevear United States 7 200 0.7× 173 0.8× 44 0.3× 227 2.0× 96 1.0× 9 429
Erika Bujáki United Kingdom 7 185 0.6× 330 1.6× 25 0.2× 76 0.7× 90 0.9× 13 418
Rahnuma Wahid United States 8 226 0.8× 247 1.2× 23 0.2× 99 0.9× 80 0.8× 17 402

Countries citing papers authored by Longfa Xu

Since Specialization
Citations

This map shows the geographic impact of Longfa Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Longfa Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Longfa Xu more than expected).

Fields of papers citing papers by Longfa Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Longfa Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Longfa Xu. The network helps show where Longfa Xu may publish in the future.

Co-authorship network of co-authors of Longfa Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Longfa Xu. A scholar is included among the top collaborators of Longfa Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Longfa Xu. Longfa Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Dongqing, Longfa Xu, Z. J. Ke, et al.. (2025). Construction of a Vero cell line expression human KREMEN1 for the development of CVA6 vaccines. Virology Journal. 22(1). 12–12. 1 indexed citations
2.
Zhao, Xiaoyu, Rui Qiao, Longfa Xu, et al.. (2024). Vascular endothelial growth factor receptor 2 as a potential host target for the inhibition of enterovirus replication. Journal of Virology. 98(10). e0112924–e0112924. 1 indexed citations
3.
Zhao, Huan, Yu Kang, Che Liu, et al.. (2023). Investigating the virulence of coxsackievirus B6 strains and antiviral treatments in a neonatal murine model. Antiviral Research. 221. 105781–105781. 3 indexed citations
4.
Li, Xiaoyuan, Yuexiang Li, Shiyong Fan, et al.. (2022). Discovery and Optimization of Quinoline Analogues as Novel Potent Antivirals against Enterovirus D68. Journal of Medicinal Chemistry. 65(21). 14792–14808. 9 indexed citations
5.
Zhou, Zhenhong, Rui Zhu, Hong-Wei Yang, et al.. (2022). Development of a rapid neutralization testing system for Rhinovirus C15 based on the enzyme-linked immunospot assay. Frontiers in Microbiology. 13. 983656–983656.
6.
Wu, Yuanyuan, Zhichao Yin, Rui Zhu, et al.. (2022). Development of a rapid neutralization assay for the detection of neutralizing antibodies against coxsackievirus B1. Diagnostic Microbiology and Infectious Disease. 103(2). 115676–115676. 1 indexed citations
7.
Li, Shuxuan, Huan Zhao, Hong-Wei Yang, et al.. (2019). Rapid Neutralization Testing System for Zika Virus Based on an Enzyme-Linked Immunospot Assay. ACS Infectious Diseases. 6(5). 811–819. 9 indexed citations
8.
Liu, Dongxiao, Longfa Xu, Rui Zhu, et al.. (2019). Development of an efficient neutralization assay for Coxsackievirus A10. Applied Microbiology and Biotechnology. 103(4). 1931–1938. 6 indexed citations
9.
Mao, Qunying, Shiyang Sun, Kelei Li, et al.. (2019). A potential therapeutic neutralization monoclonal antibody specifically against multi-coxsackievirus A16 strains challenge. Human Vaccines & Immunotherapeutics. 15(10). 2343–2350. 15 indexed citations
10.
Zhou, Bing, Longfa Xu, Rui Zhu, et al.. (2018). A bispecific broadly neutralizing antibody against enterovirus 71 and coxsackievirus A16 with therapeutic potential. Antiviral Research. 161. 28–35. 16 indexed citations
11.
Zhu, Rui, Longfa Xu, Qingbing Zheng, et al.. (2018). Discovery and structural characterization of a therapeutic antibody against coxsackievirus A10. Science Advances. 4(9). eaat7459–eaat7459. 20 indexed citations
12.
Li, Shuxuan, Huan Zhao, Lisheng Yang, et al.. (2017). A neonatal mouse model of coxsackievirus A10 infection for anti-viral evaluation. Antiviral Research. 144. 247–255. 26 indexed citations
13.
Wu, Yangtao, Rui Zhu, Longfa Xu, et al.. (2017). A novel combined vaccine based on monochimeric VLP co-displaying multiple conserved epitopes against enterovirus 71 and varicella-zoster virus. Vaccine. 35(20). 2728–2735. 17 indexed citations
14.
Zhu, Rui, Jian Liu, Chun-Ye Chen, et al.. (2016). A highly conserved epitope-vaccine candidate against varicella-zoster virus induces neutralizing antibodies in mice. Vaccine. 34(13). 1589–1596. 15 indexed citations
15.
Yang, Lisheng, Shuxuan Li, Yajing Liu, et al.. (2015). Construction and characterization of an infectious clone of coxsackievirus A6 that showed high virulence in neonatal mice. Virus Research. 210. 165–168. 21 indexed citations
16.
Hou, Wangheng, Lisheng Yang, Longfa Xu, et al.. (2015). Development of a coxsackievirus A16 neutralization test based on the enzyme-linked immunospot assay. Journal of Virological Methods. 215-216. 56–60. 10 indexed citations
17.
Hou, Wangheng, Lisheng Yang, Shuxuan Li, et al.. (2015). Construction and characterization of an infectious cDNA clone of Echovirus 25. Virus Research. 205. 41–44. 9 indexed citations
18.
Xu, Longfa, Lisheng Yang, Zhiqun Li, et al.. (2015). A Broadly Cross-protective Vaccine Presenting the Neighboring Epitopes within the VP1 GH Loop and VP2 EF Loop of Enterovirus 71. Scientific Reports. 5(1). 12973–12973. 39 indexed citations
19.
20.
Li, Zhiqun, Longfa Xu, Lisheng Yang, et al.. (2014). In Vivo Time-Related Evaluation of a Therapeutic Neutralization Monoclonal Antibody against Lethal Enterovirus 71 Infection in a Mouse Model. PLoS ONE. 9(10). e109391–e109391. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Damian Guang Wei Foo Breakdown of academic impact, for papers by Qunying Mao Breakdown of academic impact, for papers by Yanchun Che Breakdown of academic impact, for papers by Thomas Wilton Breakdown of academic impact, for papers by Chenghong Dong Breakdown of academic impact, for papers by Ken Honzumi Breakdown of academic impact, for papers by Juhana Santti Breakdown of academic impact, for papers by D.C. Pevear Breakdown of academic impact, for papers by Erika Bujáki Breakdown of academic impact, for papers by Rahnuma Wahid
Rankless by CCL
2026